3Risch NJ. Searching for genetic determinants in the new millennium [J]. Nature,2000,405:847- 856.
4Weinshilboum R. Inheritance and drug response [J]. N Engl J Med,2003,348:529- 537.
5Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy [J]. Cancer Treat Rev,1998,24:331- 344.
6Rosell R,Lord RV,Taron M,et al. DNA repair and cisplatin resistance in non-small-cell lung cancer [J]. Lung Cancer,2002,38:217- 227.
7Lunn RM,Langlois RG,Hsieh LL,et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency [J]. Cancer Res,1999,59:2557- 2561.
8Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346:92- 98.
9Zatloukal P,Petruzelka L,Zemanova M,et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage Ⅲ b and Ⅳ non-small cell lung cancer: a phase Ⅲ randomized trial [J]. Lung Cancer,2003,41:321- 331.
10Xing D,Qi J,Lin D,et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population [J]. Int J Cancer,2002,100:600- 605.
